Autoimmune diseaseImmunology & inflammationDermatology Other/Unclassified

Efalizumab PASI response dynamics

Reference paper ↗

A reduced pharmacodynamic turnover model representing the time course of PASI response toward an efalizumab-associated steady state.

Therapeutic
Efalizumab, Efalizumab / hu1124 / Raptiva
Modality
Monoclonal antibody
Target
ITGAL, CD11a, LFA-1 alpha
Disease
Plaque psoriasis
Model type
Other/Unclassified

Complete model workspace

Checking workspace access…

Parameters
2
States
2
Equations
2
Derived outputs
6

Explore this model

Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.

Gottlieb escalating-dose PASI progression

How do the response time scale and treatment-associated steady state determine PASI dynamics? Explore this biological starting configuration through PASI score, Current PASI response, PASI change rate.

Starting result

This result reflects the starting settings. Run your changes to update it.

Result preview could not load

The generated result could not be loaded. The inputs remain available below.

Starting configuration

Time: 0–1,176 hour; step 24

InputDefaultAvailable range
Effect equilibration time397 hour198.5–595.5 hour
Steady-state PASI score14.8 dimensionless7.4–22.2 dimensionless

Expected readouts

PASI score (dimensionless) · Current PASI response · PASI change rate

Adjustable model parameters

This public explorer exposes 2 curated parameters. Sign in to edit all 2 declared model parameters.

How the model represents the biology

A reduced pharmacodynamic turnover model representing the time course of PASI response toward an efalizumab-associated steady state.

How do the treated PASI steady state and response timescale determine PASI?A treatment-associated PASI steady state defines the attractor and a response half-time defines the relaxation rate. Together they drive the current PASI score toward that steady state.BIOLOGY OVERVIEWHow do the treated PASI steady state and response timescale determine PASI?Treated PASI set pointScenario-defined steady stateResponse half-timeSets first-order ratePASI relaxationMovement toward treated setpointCurrent PASI scoreDelayed skin-disease responsePRIMARY READOUTSPASI scorePASI scoreCurrent PASI responseCurrent PASI responsePASI response rate constantPASI response rate constant

Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.

Model scope: Efalizumab PK, FcRn disposition, dose delivery, CD11a/LFA-1 engagement, and immune signaling are outside this reduced PASI-turnover release.

Modeled relationships (3)
  • Treated PASI set point → PASI relaxation: sets attractor (modulation)
  • Response half-time → PASI relaxation: sets rate (modulation)
  • PASI relaxation → Current PASI score: first-order change (modulation)

Modeled relationships: Treated PASI set point to PASI relaxation: sets attractor (modulation); Response half-time to PASI relaxation: sets rate (modulation); PASI relaxation to Current PASI score: first-order change (modulation).

Primary readouts: PASI score; Current PASI response; PASI response rate constant.

Found a scientific issue? Email helpdesk@unibiointelligence.com with model ID chetty_2014_efalizumab_fcrn_pbpk_pd.

Research use only — not for patient-specific prediction or dosing advice.

Ubi Biologics